Since the inception of the current initiative, the company has acquired 987,461 shares at a total cost of approximately $6.18 million. Management maintains that the current stock price fails to capture the firm's true underlying value, prompting the board to authorize the extension as a strategic deployment of cash reserves. All shares purchased under this mandate are slated to be returned to the treasury and cancelled.

Oppenheimer & Co., Inc. remains the designated broker for the program, which may involve open market transactions conducted under SEC Rule 10b-18 and Rule 10b5-1 guidelines. Execution remains subject to prevailing market conditions and available liquidity, with the company drawing directly from existing cash and cash equivalents to fund the remainder of the $20 million authorization.